NeuroMarker Assessment for Parkinson's Disease Mild Cognitive Impairment
exploratorybiomarker · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify mild cognitive impairment in patients with Parkinson's disease and potentially flag early or subthreshold cognitive impairment.
Pilot study of a 10-minute self-administered tablet-based Altoida NeuroMarker assessment with thirteen task challenges, comparing machine-learning and augmented-reality-based MCI classification against clinician-led classification.
2026 pilot study published in Frontiers in Aging Neuroscience.
In 21 Parkinson's disease patients, NeuroMarker identified all six clinician-classified PD-MCI cases; reported sensitivity was 100%, specificity 26.7%, accuracy 47.6%, and Cohen's kappa 0.17. Interpretation was limited by wide confidence intervals, low agreement, small sample size, and lack of longitudinal confirmation.
Altoida Digital Cognitive Assessment for MCI and Amyloid Digital Neuro Signature
exploratorybiomarker · high · Fri Jan 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Establish clinical validity for Altoida's digital biomarker assessment in cognitively normal and mild cognitive impairment populations, including recognition of MCI and MCI with likelihood of amyloid pathology.
Clinical study in which participants use the Altoida app; de-identified sensor data are used to train machine-learning algorithms, with repeat visits for test-retest reliability and optional testing of an updated app variation.
Clinical trial record published on 2024-01-12 for detecting MCI and amyloid digital neuro signatures.
Deep Neuro Signatures for Alzheimer's Disease Progression Monitoring
exploratoryresearch program · medium · Mon Jan 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Detect and monitor functional impairments and disease progression in Alzheimer's disease earlier and more objectively than traditional clinical scales or caregiver-reported questionnaires.
Clinical study using remote measurement technologies such as smartphones, wearable devices, and home-based monitoring devices to measure behavioral and biological parameters associated with activities of daily living.
Clinical trial record published on 2022-01-31 for diagnosis and monitoring of disease progression using Deep Neuro Signatures.
ALTOIDA System Neuro Motor Index for Alzheimer's Disease Diagnosis
exploratorybiomarker · high · Mon Oct 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate the ALTOIDA System as a tool to assist physicians in diagnosing Alzheimer's disease in real-world clinical settings.
Clinical study of a computerized complex instrumental activities of daily living marker, using well-characterized training sets to optimize Neuro Motor Index prognosis classifiers and reproduce ALTOIDA tests in real-world clinical settings.
Clinical trial record published on 2016-10-17 for evaluation of the ALTOIDA Neuro Motor Index marker.
The supplied record states the tool remains investigational and is not standalone diagnostic; data should be used only as additional information alongside the physician's clinical impression.
Altoida NeuroMarker Platform
exploratoryplatform · high
Detect early cognitive decline and support faster neurological diagnostics, initially for mild cognitive impairment and Alzheimer's disease with potential expansion into other central nervous system diseases.
Self-administered digital cognitive assessment using neuroscience-driven tasks and multimodal sensor capture including motion, speech, and touch data, analyzed with machine learning to generate digital biomarkers.
Platform described as investigational use only and deployed as the basis for clinical validation studies and disease-specific assessments.
Speech Analysis System for Detecting Cognitive Decline
undisclosedbiomarker · low
Detect cognitive decline using speech analysis.
Patented system and method for analyzing speech to detect cognitive decline.
Chinese patent CN113710147B listed in supplied public records.
